Literature DB >> 2720652

Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.

N S Burres1, J J Clement.   

Abstract

Three novel heterocyclic compounds, mycalamide-A and -B and onnamide, were isolated from Mycale sp. and Theonella sp. sponges collected in New Zealand and Okinawan waters. Each exhibited potent in vitro toxicity and in vivo efficacy against murine and human tumor cells. Concentrations of each that inhibited replication of cultured murine lymphoma P388 cells by 50% were 5 nM or less. Mycalamide-A and -B were also potent inhibitors of HL-60, HT-29, and A549 human tumor cell replication (50% inhibitory concentration less than 5 nM), while values for onnamide were greater (50% inhibitory concentrations between 25 and 200 nM). Mycalamide-A (10 micrograms/kg) and -B (2.5 micrograms/kg) were moderately active against P388 leukemia (increase in life span, approximately 50%), while onnamide was inactive (40 micrograms/kg; increase in life span, 15%). Mycalamide-A was also active against B16 melanoma, Lewis lung carcinoma, M5076 ovarian sarcoma, colon 26 carcinoma, and the human MX-1, CX-1, and Burkitt's lymphoma tumor xenografts. Mechanism of action studies indicate that the three agents inhibited protein synthesis. For example, after 1-h exposures to 20 nM mycalamide-A and -B, the rates of [3H]leucine incorporation into acid-precipitable material of cultured P388 cells were inhibited 54 and 99%, while the effects on incorporation of [3H]uridine and [3H]thymidine were less. The relative effects of 20 to 2000 nM mycalamide-A on protein, RNA, and DNA synthesis were consistent with those observed during exposure of P388 cells to 1 microM emetine, a known inhibitor of protein synthesis. Also, the three agents inhibited translation of RNA into protein in a cell-free lysate of rabbit reticulocytes. Although mycalamide-A disrupted DNA metabolism, the agent apparently did not intercalate into DNA, and a mixture of four deoxynucleosides (250 microM each) did not decrease the antiproliferative effects of the agent. Collectively, these data indicate that this class of compounds represents novel antitumor agents which should be further evaluated to define their potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720652

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

2.  Synthesis of psymberin analogues: probing a functional correlation with the pederin/mycalamide family of natural products.

Authors:  Xin Jiang; Noelle Williams; Jef K De Brabander
Journal:  Org Lett       Date:  2007-01-18       Impact factor: 6.005

3.  Studies toward the asymmetric synthesis of the right part of the mycalamides.

Authors:  H Marlon Zhong; Jeong-Hun Sohn; Viresh H Rawal
Journal:  J Org Chem       Date:  2007-01-19       Impact factor: 4.354

4.  Total synthesis of theopederin D.

Authors:  Michael E Green; Jason C Rech; Paul E Floreancig
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Irciniastatin A, a pederin-type translation inhibitor, promotes ectodomain shedding of cell-surface tumor necrosis factor receptor 1.

Authors:  Seiya Hirano; Hue Tu Quach; Tsubasa Watanabe; Naoki Kanoh; Yoshiharu Iwabuchi; Takeo Usui; Takao Kataoka
Journal:  J Antibiot (Tokyo)       Date:  2015-01-28       Impact factor: 2.649

6.  Metallacycle-Mediated Cross-Coupling in Natural Product Synthesis.

Authors:  Natasha F O'Rourke; Matthew J Kier; Glenn C Micalizio
Journal:  Tetrahedron       Date:  2016-09-07       Impact factor: 2.457

7.  Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity.

Authors:  A Jonathan Singh; Chun-Xiao Xu; Xiaoming Xu; Lyndon M West; Anja Wilmes; Ariane Chan; Ernest Hamel; John H Miller; Peter T Northcote; Arun K Ghosh
Journal:  J Org Chem       Date:  2010-01-01       Impact factor: 4.354

8.  Antitumor activity and mechanism of action of the marine compound girodazole.

Authors:  F Lavelle; A Zerial; C Fizames; B Rabault; A Curaudeau
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

Review 9.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

Review 10.  Antiviral lead compounds from marine sponges.

Authors:  Sunil Sagar; Mandeep Kaur; Kenneth P Minneman
Journal:  Mar Drugs       Date:  2010-10-11       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.